



Corporate Legal Division

2800 Plymouth Road
Ann Arbor, MI 48105
FAX: (313) 996-1553

#14

To: Karin Tyson	Re: Patent No. 4,260,769-Cerebyx®
Fax: 703-308-6916	Date: October 31, 1996
From: Todd Crissey	Pages Sent: (w/fax cover) 3
If this fax is not received clearly, call (313) 996-1607	

NOTICE: This facsimile is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure. If the reader of this facsimile is not the intended recipient, or an employee or agent responsible for delivering the facsimile to the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of the communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately at the telephone number(s) listed above and return the original facsimile to us at the above address by U.S. mail, the cost of which will be reimbursed. Thank you.

TODD M. CRISSEY - (313) 996-7530

Message:

Dear Ms. Tyson:

Pursuant to your request, the attached document details the chain of title of the above-identified U.S. patent for which a Request for Patent Term Extension under 35 U.S.C. § 156 has been submitted.

Please feel free to contact me if you have any additional questions.



Todd M. Crissey

Hard copy to follow via Courier.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 4,260,769
Issue Date: April 7, 1981
Patentees: Valentino J. Stella and
Kenneth B. Sloan
Title: 5,5-Diphenylhydantoins

Establishing Right of Assignee to Prosecute under 37 C.F.R. § 3.73(b)

Box Patent Ext.
Commissioner of Patents and Trademarks
Washington, D.C. 20231

Commissioner of Patents and Trademarks:

Merck & Co., Inc., the assignee of the entire right, title and interest in the above-identified patent desires to take action, through their designated agent, Warner-Lambert Company, to extend the term of the above-identified patent under 35 U.S.C. § 156.

In accordance with the requirements of 37 C.F.R. § 3.73(b), the following information shows a chain of title from the original owner to Merck & Co., Inc.

1. The above-identified patent (the '769 patent) issued to INTERx Research Corporation. An assignment from inventors Valentino J. Stella and Kenneth B. Sloan to INTERx Research Corporation is recorded at reel 3412, frame 211.
2. INTERx Research Corporation was merged into Merck and Company, Incorporated, a wholly owned subsidiary of Merck & Co., Inc. Copies of the merger papers have been recorded. The reel and frame numbers are not yet available. A copy of the documents recorded are attached as Exhibit 1.
3. Merck & Co., Inc. granted to American Hospital Supply Corporation, American Critical Care Division, an exclusive licensee to the '769 patent under an Option and License Agreement dated August 14, 1984.
4. American Hospital Supply Corporation assigned its exclusive license rights to the '769 patent to E. I. DuPont De Nemours and Company (DuPont) under an Asset Purchase Agreement dated July 3, 1986.
5. DuPont sublicensed its exclusive license rights to the '769 patent to Warner-Lambert Company under a License Agreement dated January 19, 1990.

6. DuPont assigned it rights to the '769 patent and it rights and obligations with respect to the Warner-Lambert License Agreement to The DuPont Merck Pharmaceutical Company (DuPont Merck) under an Asset Contribution Agreement dated January 1, 1991. An assignment of the license rights was recorded at reel 5955 and frames 010-028. This assignment was intended to make of record the transfer of license rights. DuPont and DuPont Merck hereby acknowledge that the '769 patent is assigned to and owned by Merck & Co., Inc.

Certification by Merck & Co., Inc.


Merck & Co., Inc. has reviewed the evidentiary documents submitted to show chain of title and hereby certifies that, to the best of its knowledge and belief, title to U.S. Patent No. 4,260,769 is in Merck and Co., Inc.

By:

Printed Name:

Title:


Date:


Joseph F. DiPrima
Assistant General Counsel
October 14, 1996

Acknowledgment by DuPont, DuPont Merck and Warner-Lambert

We hereby acknowledge that the statements made above are, to the best of our knowledge and belief, accurate.


E. I DuPont De Nemours and Company

By: 
Printed Name: Carl G. Bartholomew
Title: Corporate Counsel
Date: 10/26/96

The DuPont Merck Pharmaceutical Company

By:  BGF
Printed Name: Don M. Kerr
Title: Vice President, Associate General Counsel
Date: 10/15/96

Warner-Lambert Company

By: 
Printed Name:
Title: Ronald M. Cresswell, Ph.D., F.R.S.E.
Vice President and Chairman
Date: 10/30/96 Parke-Davis Pharmaceutical Research
Warner-Lambert Company

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 4,260,769

Issue Date: April 7, 1981

Patentees: Valentino J. Stella and

Kenneth B. Sloan

Title: 5,5-Diphenylhydantoins

Establishing Right of Assignee to Prosecute under 37 C.F.R. § 3.73(b)

Box Patent Ext.

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Commissioner of Patents and Trademarks:

Merck & Co., Inc., the assignee of the entire right, title and interest in the above-identified patent desires to take action, through their designated agent, Warner-Lambert Company, to extend the term of the above-identified patent under 35 U.S.C. § 156.

In accordance with the requirements of 37 C.F.R. § 3.73(b), the following information shows a chain of title from the original owner to Merck & Co., Inc.

1. The above-identified patent (the '769 patent) issued to INTERx Research Corporation. An assignment from inventors Valentino J. Stella and Kenneth B. Sloan to INTERx Research Corporation is recorded at reel 3412, frame 211.
2. INTERx Research Corporation was merged into Merck and Company, Incorporated, a wholly owned subsidiary of Merck & Co., Inc. Copies of the merger papers have been recorded. The reel and frame numbers are not yet available. A copy of the documents recorded are attached as Exhibit 1.
3. Merck & Co., Inc. granted to American Hospital Supply Corporation, American Critical Care Division, an exclusive licensee to the '769 patent under an Option and License Agreement dated August 14, 1984.
4. American Hospital Supply Corporation assigned its exclusive license rights to the '769 patent to E. I. DuPont De Nemours and Company (DuPont) under an Asset Purchase Agreement dated July 3, 1986.
5. DuPont sublicensed its exclusive license rights to the '769 patent to Warner-Lambert Company under a License Agreement dated January 19, 1990.

6. DuPont assigned it rights to the '769 patent and it rights and obligations with respect to the Warner-Lambert License Agreement to The DuPont Merck Pharmaceutical Company (DuPont Merck) under an Asset Contribution Agreement dated January 1, 1991. An assignment of the license rights was recorded at reel 5955 and frames 010-028. This assignment was intended to make of record the transfer of license rights. DuPont and DuPont Merck hereby acknowledge that the '769 patent is assigned to and owned by Merck & Co., Inc.

Certification by Merck & Co., Inc.

Merck & Co., Inc. has reviewed the evidentiary documents submitted to show chain of title and hereby certifies that, to the best of its knowledge and belief, title to U.S. Patent No. 4,260,769 is in Merck and Co., Inc.

By:

Printed Name:

Title:

Date:

Joseph F. DiPrima
Joseph F. DiPrima
Assistant General Counsel
October 14, 1996

Log # 28,944

Acknowledgment by DuPont, DuPont Merck and Warner-Lambert

We hereby acknowledge that the statements made above are, to the best of our knowledge and belief, accurate.

E. I DuPont De Nemours and Company

By: *Carl G. Bartholomew*
Printed Name: Carl G. Bartholomew
Title: Corporate Counsel
Date: 10/26/96

The DuPont Merck Pharmaceutical Company

By: *Don M. Kerr*
Printed Name: Don M. Kerr
Title: Vice President, Associate General Counsel
Date: 10/15/96

Warner-Lambert Company

By: *Ronald M. Crosswell*
Printed Name:
Title: Ronald M. Crosswell, Ph.D., F.R.S.E.
Vice President and Chairman
Date: 10/30/96
Parke-Davis Pharmaceutical Research
Warner-Lambert Company